Hypoxic Sensitizers: Radiobiological Studies at the Cellular Level

Overview

Journal Radiology

Specialty Radiology

Date 1975 Nov 1

PMID 1178881

Citations 51

Authors

E J Hall

Affiliations

Soon will be listed here.

Abstract

The nitroimidazoles have been found to selectively sensitize hypoxic cells to the effects of irradiation. The latest in this family of drugs is RO-07-0582, which is able to mimic 80% of the oxygen effect at a concentration of 5 mM by modifying the sensitivity of hypoxic cells to single doses of gamma rays; however, it is not a substitution for oxygen in promoting the repair of sublethal radiation damage between split doses. Studies show that it is a powerful cytotoxic agent as well and selectively operates against hypoxic cells.

Citing Articles

Hypoxia-targeted drug delivery.

Sharma A, Arambula J, Koo S, Kumar R, Singh H, Sessler J Chem Soc Rev. 2018; 48(3):771-813.

PMID: 30575832 PMC: 6361706. DOI: 10.1039/c8cs00304a.

The experimental development of bioreductive drugs and their role in cancer therapy.

Workman P, Stratford I Cancer Metastasis Rev. 1993; 12(2):73-82.

PMID: 8375022 DOI: 10.1007/BF00689802.

Cellular approaches to bioreductive drug mechanisms.

Rauth A, Marshall R, Kuehl B Cancer Metastasis Rev. 1993; 12(2):153-64.

PMID: 8375018 DOI: 10.1007/BF00689807.

Sulphydryls, ascorbate and oxygen as modifiers of the toxicity and metabolism of misonidazole in vitro.

Taylor Y, Rauth A Br J Cancer. 1980; 41(6):892-900.

PMID: 7426314 PMC: 2010364. DOI: 10.1038/bjc.1980.166.

Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity.

Workman P, Bleehen N, Wiltshire C Br J Cancer. 1980; 41(2):302-4.

PMID: 7370170 PMC: 2010192. DOI: 10.1038/bjc.1980.43.